Medicare Spending on Drugs With Accelerated Approval-Reference-Cited by-同舟云学术

Medicare Spending on Drugs With Accelerated Approval

Published:2022-07 Issue:7 Volume:175 Page:938-944
ISSN:0003-4819
Container-title:Annals of Internal Medicine
language:en
Short-container-title:Ann Intern Med

Author:

Ballreich Jeromie¹^ORCID,Socal Mariana¹^ORCID,Bennett Charles L.²,Schoen Martin W.³^ORCID,Trujillo Antonio⁴^ORCID,Xuan Andrew⁵^ORCID,Anderson Gerard¹

Affiliation:

1. Department of Health Policy & Management and Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (J.B., M.S., G.A.)

2. University of South Carolina College of Pharmacy, Columbia, South Carolina, and the Center for Comparative Effectiveness Research, the Beckman Institute, and the City of Hope Comprehensive Cancer Center, Duarte, California (C.L.B.)

3. Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri (M.W.S.)

4. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (A.T.)

5. Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (A.X.).

Publisher

American College of Physicians

Subject

General Medicine,Internal Medicine

Reference18 articles.

1. Fulfilling the Mandate of the US Food and Drug Administration’s Accelerated Approval Pathway

2. Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018

3. Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication

4. Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval

5. Paying for Cancer Drugs That Prove Their Benefit

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Evidence Supporting FDA Approval of Gene and RNA Therapies for Rare Inherited Conditions;Pediatric Drugs;2024-08-05

2. Drug development for major chronic health conditions—aligning with growing public health needs: Proceedings from a multistakeholder think tank;American Heart Journal;2024-04

3. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy;The European Journal of Health Economics;2023-11-14

4. Pediatric Drugs, Accelerated Approval, and Prospects for Reform;Pediatric Drugs;2023-10-14

5. Commercial Health Plan and Enrollee Out-of-Pocket Spending on Accelerated Approval Products in 2019;JAMA Internal Medicine;2023-09-01